<!DOCTYPE html><html lang="en"><head><meta charset="UTF-8"><meta name="viewport" content="width=device-width,initial-scale=1.0"><title>Lab Tests — Diabetes Guide</title><link rel="stylesheet" href="styles.css"></head><body>
<nav class="navbar"><div class="navbar-inner"><a class="brand" href="index.html">Diabetes Guide</a><a class="home-link" href="index.html">All Topics</a></div></nav>
<div class="container">
<div class="page-header"><h1>Lab Tests for Diabetes</h1><p>Essential blood tests for diagnosis, monitoring, and complication screening</p></div>

<div class="illus">
<svg width="280" height="100" viewBox="0 0 280 100" xmlns="http://www.w3.org/2000/svg">
<!-- Test tube 1 -->
<rect x="40" y="15" width="24" height="60" rx="4" fill="#dbeafe" stroke="#3182ce" stroke-width="2"/>
<rect x="40" y="45" width="24" height="30" rx="0 0 4 4" fill="#3182ce" opacity="0.6">
  <animate attributeName="height" values="30;20;30" dur="3s" repeatCount="indefinite"/>
  <animate attributeName="y" values="45;55;45" dur="3s" repeatCount="indefinite"/>
</rect>
<rect x="36" y="12" width="32" height="6" rx="2" fill="#3182ce"/>
<text x="52" y="90" text-anchor="middle" font-size="8" fill="#3182ce" font-weight="600">FPG</text>
<!-- Test tube 2 -->
<rect x="128" y="15" width="24" height="60" rx="4" fill="#dcfce7" stroke="#38a169" stroke-width="2"/>
<rect x="128" y="40" width="24" height="35" rx="0 0 4 4" fill="#38a169" opacity="0.6">
  <animate attributeName="height" values="35;25;35" dur="2.5s" repeatCount="indefinite"/>
  <animate attributeName="y" values="40;50;40" dur="2.5s" repeatCount="indefinite"/>
</rect>
<rect x="124" y="12" width="32" height="6" rx="2" fill="#38a169"/>
<text x="140" y="90" text-anchor="middle" font-size="8" fill="#38a169" font-weight="600">HbA1c</text>
<!-- Test tube 3 -->
<rect x="216" y="15" width="24" height="60" rx="4" fill="#fef3c7" stroke="#e8913a" stroke-width="2"/>
<rect x="216" y="35" width="24" height="40" rx="0 0 4 4" fill="#e8913a" opacity="0.6">
  <animate attributeName="height" values="40;28;40" dur="3.5s" repeatCount="indefinite"/>
  <animate attributeName="y" values="35;47;35" dur="3.5s" repeatCount="indefinite"/>
</rect>
<rect x="212" y="12" width="32" height="6" rx="2" fill="#e8913a"/>
<text x="228" y="90" text-anchor="middle" font-size="8" fill="#e8913a" font-weight="600">OGTT</text>
</svg>
</div>

<div class="section">
<h2><span class="icon-sm">&#x1F4CB;</span> Overview</h2>
<p>Laboratory testing is fundamental to every aspect of diabetes care — from initial diagnosis to ongoing monitoring and screening for complications. Understanding what each test measures, when it should be done, and what the results mean empowers patients to participate actively in their care.</p>
</div>

<div class="section">
<h2><span class="icon-sm">&#x1F9EA;</span> Glycemic Tests</h2>

<h3>HbA1c (Glycated Hemoglobin)</h3>

<div class="gauge-row">
<div class="gauge"><div class="gauge-circle green" style="--pct:57%"><span>&lt;5.7%</span></div><div class="gauge-label">Normal</div></div>
<div class="gauge"><div class="gauge-circle orange" style="--pct:64%"><span>5.7-6.4%</span></div><div class="gauge-label">Prediabetes</div></div>
<div class="gauge"><div class="gauge-circle red" style="--pct:80%"><span>&ge;6.5%</span></div><div class="gauge-label">Diabetes</div></div>
</div>
<p>HbA1c measures the percentage of hemoglobin in red blood cells that has glucose attached to it. Because red blood cells live approximately 120 days, HbA1c reflects average blood glucose over the preceding <strong>2–3 months</strong> (with greater weighting toward the most recent 30 days).</p>
<ul>
<li><strong>Use:</strong> Diagnosis of diabetes and prediabetes; primary metric for monitoring long-term glycemic control.</li>
<li><strong>Target:</strong> &lt; 7.0% for most adults with diabetes (individualized targets may be lower or higher).</li>
<li><strong>Frequency:</strong> Every 3 months if not at target; every 6 months if stable.</li>
<li><strong>Approximate glucose equivalents:</strong> HbA1c of 7% corresponds to an estimated average glucose (eAG) of ~154 mg/dL. Each 1% change in HbA1c corresponds to approximately 28–29 mg/dL change in eAG.</li>
</ul>

<div class="table-wrap">
<table>
<thead>
<tr><th>HbA1c (%)</th><th>Estimated Average Glucose (mg/dL)</th><th>Estimated Average Glucose (mmol/L)</th></tr>
</thead>
<tbody>
<tr><td>5.0</td><td>97</td><td>5.4</td></tr>
<tr><td>5.7</td><td>117</td><td>6.5</td></tr>
<tr><td>6.0</td><td>126</td><td>7.0</td></tr>
<tr><td>6.5</td><td>140</td><td>7.8</td></tr>
<tr><td>7.0</td><td>154</td><td>8.6</td></tr>
<tr><td>8.0</td><td>183</td><td>10.2</td></tr>
<tr><td>9.0</td><td>212</td><td>11.8</td></tr>
<tr><td>10.0</td><td>240</td><td>13.4</td></tr>
</tbody>
</table>
</div>

<div class="warning">
<strong>Conditions That Affect HbA1c Accuracy:</strong> HbA1c may be falsely high or low in patients with hemoglobin variants (sickle cell trait/disease, thalassemia), iron deficiency anemia, chronic kidney disease, recent blood loss or transfusion, pregnancy, or hemolytic anemia. In these cases, fructosamine or glucose monitoring (SMBG/CGM) should be used instead.
</div>

<h3>Fasting Plasma Glucose (FPG)</h3>
<ul>
<li><strong>What it measures:</strong> Blood glucose after an overnight fast of at least 8 hours (no caloric intake).</li>
<li><strong>Use:</strong> Diagnosis of diabetes and prediabetes; monitoring fasting glucose control.</li>
<li><strong>Normal:</strong> &lt; 100 mg/dL | <strong>Prediabetes:</strong> 100–125 mg/dL | <strong>Diabetes:</strong> &ge; 126 mg/dL</li>
</ul>

<h3>Post-Prandial Glucose (PPG)</h3>
<ul>
<li><strong>What it measures:</strong> Blood glucose 1–2 hours after the start of a meal.</li>
<li><strong>Use:</strong> Assessing how well the body handles glucose after eating; particularly important for managing mealtime insulin doses.</li>
<li><strong>Target:</strong> &lt; 180 mg/dL at 1–2 hours post-meal (ADA); &lt; 140 mg/dL (IDF/AACE for more stringent targets).</li>
<li><strong>Significance:</strong> Post-prandial spikes contribute significantly to HbA1c, especially when HbA1c is between 7–8%. They are also independently associated with cardiovascular risk.</li>
</ul>

<h3>Oral Glucose Tolerance Test (OGTT)</h3>
<ul>
<li><strong>Procedure:</strong> After overnight fasting, the patient drinks 75 grams of glucose dissolved in water. Blood glucose is measured at fasting and at 2 hours.</li>
<li><strong>Use:</strong> Diagnosis of diabetes, prediabetes (IGT), and gestational diabetes. The OGTT is the most sensitive test for detecting IGT.</li>
<li><strong>Normal:</strong> 2-hour glucose &lt; 140 mg/dL | <strong>IGT:</strong> 140–199 mg/dL | <strong>Diabetes:</strong> &ge; 200 mg/dL</li>
<li><strong>For gestational diabetes:</strong> A modified version (using different glucose loads and cutoffs) is used during pregnancy at 24–28 weeks.</li>
</ul>
</div>

<div class="section">
<h2><span class="icon-sm">&#x1F4C9;</span> Insulin and Beta-Cell Function Tests</h2>

<h3>Fasting Insulin</h3>
<ul>
<li><strong>What it measures:</strong> The level of insulin in the blood after an overnight fast.</li>
<li><strong>Use:</strong> Assessing insulin resistance. Elevated fasting insulin suggests the pancreas is overproducing insulin to compensate for resistance.</li>
<li><strong>Normal range:</strong> Approximately 2–25 &micro;IU/mL (varies by lab). Higher levels indicate greater insulin resistance.</li>
<li><strong>HOMA-IR:</strong> The Homeostatic Model Assessment for Insulin Resistance is calculated as: (Fasting Insulin &times; Fasting Glucose) / 405. A HOMA-IR &gt; 2.5 suggests insulin resistance.</li>
</ul>

<h3>C-Peptide</h3>
<ul>
<li><strong>What it measures:</strong> C-peptide is a byproduct released in equal amounts when proinsulin is cleaved to form insulin. It reflects endogenous (body's own) insulin production.</li>
<li><strong>Use:</strong> Distinguishing Type 1 from Type 2 diabetes; assessing residual beta-cell function; evaluating insulin needs.</li>
<li><strong>Normal fasting range:</strong> 0.8–3.1 ng/mL (varies by lab).</li>
<li><strong>Low/undetectable C-peptide:</strong> Indicates minimal beta-cell function — consistent with Type 1 diabetes or late-stage T2D.</li>
<li><strong>High C-peptide:</strong> Indicates hyperinsulinemia — consistent with insulin resistance (early T2D).</li>
</ul>

<div class="note">
<strong>Clinical Pearl:</strong> C-peptide is preferred over direct insulin measurement because it is not affected by exogenous insulin therapy and has a longer half-life, making it more stable and reliable.
</div>
</div>

<div class="section">
<h2><span class="icon-sm">&#x1F4CA;</span> Comprehensive Diagnostic and Screening Table</h2>
<div class="table-wrap">
<table>
<thead>
<tr><th>Test</th><th>Normal Range</th><th>Prediabetes</th><th>Diabetes</th><th>Frequency</th></tr>
</thead>
<tbody>
<tr><td>Fasting Plasma Glucose</td><td>&lt; 100 mg/dL</td><td>100–125 mg/dL</td><td>&ge; 126 mg/dL</td><td>At diagnosis; as needed</td></tr>
<tr><td>HbA1c</td><td>&lt; 5.7%</td><td>5.7–6.4%</td><td>&ge; 6.5%</td><td>Every 3–6 months</td></tr>
<tr><td>OGTT (2-hour)</td><td>&lt; 140 mg/dL</td><td>140–199 mg/dL</td><td>&ge; 200 mg/dL</td><td>At diagnosis; GDM screening</td></tr>
<tr><td>Random Plasma Glucose</td><td>—</td><td>—</td><td>&ge; 200 mg/dL + symptoms</td><td>Symptomatic patients</td></tr>
<tr><td>Fasting Insulin</td><td>2–25 &micro;IU/mL</td><td>Often elevated</td><td>Variable</td><td>As clinically indicated</td></tr>
<tr><td>C-Peptide (fasting)</td><td>0.8–3.1 ng/mL</td><td>Normal/high</td><td>Low (T1D) or high (T2D)</td><td>At diagnosis for typing</td></tr>
</tbody>
</table>
</div>
</div>

<div class="section">
<h2><span class="icon-sm">&#x2764;&#xFE0F;</span> Lipid Panel</h2>
<p>Dyslipidemia is extremely common in diabetes and is a major driver of cardiovascular disease. The typical "diabetic dyslipidemia" pattern includes:</p>
<ul>
<li>Elevated triglycerides</li>
<li>Low HDL cholesterol</li>
<li>Elevated small, dense LDL particles (even when total LDL may appear near-normal)</li>
</ul>

<div class="table-wrap">
<table>
<thead>
<tr><th>Lipid Marker</th><th>Desirable Level</th><th>Notes</th></tr>
</thead>
<tbody>
<tr><td>Total Cholesterol</td><td>&lt; 200 mg/dL</td><td>General population target</td></tr>
<tr><td>LDL Cholesterol</td><td>&lt; 100 mg/dL (or &lt; 70 if CVD)</td><td>Primary target for statin therapy</td></tr>
<tr><td>HDL Cholesterol</td><td>&gt; 40 mg/dL (men), &gt; 50 mg/dL (women)</td><td>Higher is better; protective factor</td></tr>
<tr><td>Triglycerides</td><td>&lt; 150 mg/dL</td><td>&gt; 500 mg/dL increases pancreatitis risk</td></tr>
<tr><td>Non-HDL Cholesterol</td><td>&lt; 130 mg/dL</td><td>Secondary target; total cholesterol minus HDL</td></tr>
</tbody>
</table>
</div>
<p><strong>Frequency:</strong> At diagnosis, then annually (or more often if on lipid-lowering therapy or values are abnormal).</p>
</div>

<div class="section">
<h2><span class="icon-sm">&#x1FAB7;</span> Kidney Function Tests</h2>
<p>Diabetic kidney disease (diabetic nephropathy) is the leading cause of end-stage renal disease worldwide. Early detection through regular screening allows for interventions that can slow or halt progression.</p>

<h3>eGFR (Estimated Glomerular Filtration Rate)</h3>
<ul>
<li><strong>What it measures:</strong> How well the kidneys filter waste from the blood — calculated from serum creatinine (and sometimes cystatin C), age, and sex.</li>
<li><strong>Normal:</strong> &ge; 90 mL/min/1.73m&sup2;</li>
<li><strong>Staging:</strong> Stage 1 (&ge; 90), Stage 2 (60–89), Stage 3a (45–59), Stage 3b (30–44), Stage 4 (15–29), Stage 5 (&lt; 15 — kidney failure).</li>
</ul>

<h3>Urine Albumin-to-Creatinine Ratio (UACR)</h3>
<ul>
<li><strong>What it measures:</strong> The amount of albumin (a protein) leaking into the urine — an early marker of kidney damage.</li>
<li><strong>Normal:</strong> &lt; 30 mg/g</li>
<li><strong>Moderately increased albuminuria (microalbuminuria):</strong> 30–300 mg/g — early diabetic nephropathy.</li>
<li><strong>Severely increased albuminuria (macroalbuminuria):</strong> &gt; 300 mg/g — overt nephropathy.</li>
</ul>

<p><strong>Frequency:</strong> Both eGFR and UACR should be tested annually starting at diagnosis of T2D, or 5 years after diagnosis of T1D. More frequent testing if abnormal.</p>

<div class="tip">
<strong>Treatment Implications:</strong> Patients with albuminuria should be started on an ACE inhibitor or ARB (even if blood pressure is normal) to reduce kidney damage. SGLT2 inhibitors and finerenone have also demonstrated significant kidney-protective effects in clinical trials.
</div>
</div>

<div class="section">
<h2><span class="icon-sm">&#x1F9AB;</span> Liver Function Tests</h2>
<p>Non-alcoholic fatty liver disease (NAFLD) affects an estimated 55–70% of people with T2D. Screening and monitoring are important.</p>
<ul>
<li><strong>ALT (Alanine Aminotransferase):</strong> Elevated ALT may indicate liver inflammation or damage. Persistently elevated ALT should prompt further evaluation (ultrasound, FIB-4 score).</li>
<li><strong>AST (Aspartate Aminotransferase):</strong> Less specific for liver than ALT but part of the standard panel.</li>
<li><strong>FIB-4 Index:</strong> A non-invasive score calculated from age, ALT, AST, and platelet count that estimates the degree of liver fibrosis.</li>
</ul>
<p><strong>Frequency:</strong> At baseline and periodically, especially in patients on medications that may affect the liver (e.g., statins, thiazolidinediones).</p>
</div>

<div class="section">
<h2><span class="icon-sm">&#x1F98B;</span> Thyroid Function Tests</h2>
<p>Thyroid disorders are more common in people with diabetes, especially Type 1 diabetes (autoimmune association):</p>
<ul>
<li><strong>TSH (Thyroid-Stimulating Hormone):</strong> The primary screening test. Normal range: approximately 0.4–4.0 mIU/L.</li>
<li><strong>Free T4 and Free T3:</strong> Measured if TSH is abnormal.</li>
<li><strong>Hypothyroidism:</strong> Can worsen lipid profiles, cause weight gain, and impair glucose metabolism.</li>
<li><strong>Hyperthyroidism:</strong> Can worsen glycemic control and increase insulin requirements.</li>
</ul>
<p><strong>Frequency:</strong> At diagnosis of T1D and every 1–2 years thereafter. In T2D, test if symptoms suggest thyroid dysfunction.</p>
</div>

<div class="section">
<h2><span class="icon-sm">&#x1F52C;</span> Other Important Tests</h2>

<h3>Diabetes Autoantibodies</h3>
<p>Used to confirm Type 1 diabetes or LADA: GAD65 antibodies, IA-2 antibodies, insulin autoantibodies (IAA), ZnT8 antibodies. Typically ordered when the type of diabetes is uncertain.</p>

<h3>Complete Blood Count (CBC)</h3>
<p>Helps identify anemia (which affects HbA1c accuracy), infections, and other hematologic conditions.</p>

<h3>Serum Electrolytes</h3>
<p>Potassium, sodium, and bicarbonate — important in DKA management and for patients on SGLT2 inhibitors, ACE inhibitors, or diuretics.</p>

<h3>Vitamin B12</h3>
<p>Long-term metformin use can cause vitamin B12 deficiency. The ADA recommends periodic B12 monitoring in patients on metformin, especially those with anemia or peripheral neuropathy. Normal: &gt; 300 pg/mL. Deficiency: &lt; 200 pg/mL.</p>

<h3>Uric Acid</h3>
<p>Elevated uric acid is associated with insulin resistance, metabolic syndrome, and kidney disease. May be monitored in patients with gout or CKD.</p>
</div>

<div class="section">
<h2><span class="icon-sm">&#x1F4C5;</span> Summary of Recommended Monitoring Schedule</h2>
<div class="table-wrap">
<table>
<thead>
<tr><th>Test</th><th>Frequency</th></tr>
</thead>
<tbody>
<tr><td>HbA1c</td><td>Every 3 months (if not at target) or every 6 months (if stable)</td></tr>
<tr><td>Lipid Panel</td><td>Annually (more often if on treatment)</td></tr>
<tr><td>eGFR + UACR</td><td>Annually (from diagnosis in T2D; 5 years in T1D)</td></tr>
<tr><td>Liver Function (ALT)</td><td>At baseline; periodically</td></tr>
<tr><td>TSH</td><td>At diagnosis (T1D); then every 1–2 years or if symptomatic</td></tr>
<tr><td>Vitamin B12</td><td>Periodically if on metformin (every 1–2 years)</td></tr>
<tr><td>Dilated Eye Exam</td><td>Annually (from diagnosis in T2D; 5 years in T1D)</td></tr>
<tr><td>Foot Exam</td><td>Annually (comprehensive); every visit (visual inspection)</td></tr>
<tr><td>Blood Pressure</td><td>Every visit</td></tr>
</tbody>
</table>
</div>
</div>

<div class="page-nav">
<a class="prev" href="prediabetes.html">Prediabetes</a>
<a class="next" href="blood-sugar-monitoring.html">Blood Sugar Monitoring</a>
</div>
</div>
<div class="footer">This guide is for informational purposes. Always consult a qualified endocrinologist / diabetologist.</div>
<button class="scroll-top" id="scrollTop" title="Back to top">&uarr;</button>
<script>
var sb=document.getElementById('scrollTop');window.addEventListener('scroll',function(){sb.classList.toggle('visible',window.scrollY>400)});sb.addEventListener('click',function(){window.scrollTo({top:0,behavior:'smooth'})});
document.querySelectorAll('.accordion-header').forEach(function(h){h.addEventListener('click',function(){this.parentElement.classList.toggle('open')})});
</script>
</body></html>